82 completed, 11 recruiting, 10 unknown, 9 terminated. 120 Phase 2, 20 Phase 1, 10 Phase 3.
Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lemborexant for Cannabis Use Disorder Lemborexant 10mg, Placebo, Brief Behavioural Intervention - Cannabis Use Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 28 | 2026-11-01 | 2026-09-22 |
| Combination Therapy for Alcohol Use Disorder Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets) - Alcohol Use Disorder | Phase 2 | Not yet recruiting | Johns Hopkins University | 45 | 2026-11-01 | 2026-10-01 |
| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study 12 weeks of weekly subcutaneous semaglutide injection - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | Kirby Institute | 40 | 2026-09-01 | 2026-06-26 |
| Multi-Site Trial of Tirzepatide for Smoking Cessation Tirzepatide, Placebo - Smoking Cessation, Smoking Behaviors | Phase 2 | Recruiting | University of Southern California | 300 | 2026-06-05 | 2026-07-17 |
| Accelerated dTMS Smoking Cessation Bilateral deep accelerated repetitive transcranial magnetic stimulation - Tobacco Use Disorder, Addiction Nicotine | Phase 2 | Recruiting | Waypoint Centre for Mental Health Care | 40 | 2026-02-24 | 2026-04-21 |
| Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis Standard Varenicline Dosing (1 mg BID), Bupropion 150 mg twice daily, Increased Varenicline Dosing (1mg TID) - Pancreatitis, Chronic, Pancreatitis, Acute | Phase 2 | Withdrawn | Mayo Clinic | 2025-11-06 | 2026-07-07 | |
| Tirzepatide for Alcohol Use Disorder Tirzepatide, Placebo injections - Alcohol Use Disorder, Obesity and Overweight | Phase 2 | Recruiting | University of Southern California | 42 | 2025-10-06 | 2025-10-14 |
| A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder AFA-281 - Alcohol Abuse, Alcohol Abuse/addiction | Phase 2 | Not yet recruiting | Afasci Inc | 36 | 2025-10-01 | 2024-11-29 |
| Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder LDX-01 plus TAU, Placebo plus TAU - Methamphetamine Abuse, Methamphetamine-dependence | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 80 | 2025-07-18 | 2026-02-23 |
| GLP-1R Agonist Treatment for Opioid Use Disorder Semaglutide Pen Injector, Placebo - Opioid Use Disorder, Opioid Abuse and Addiction | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 200 | 2025-01-27 | 2026-08-28 |
| Ketamine for Combined Depression and Alcohol Use Disorder Ketamine Hydrochloride, Midazolam Hydrochloride - Depression, Alcohol Use Disorder | Phase 1 / Phase 2 | Recruiting | University Hospital of North Norway | 34 | 2025-01-20 | 2026-06-23 |
| Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome | Phase 2 | Terminated | Rachel G. Greenberg, MD, MB, MHS | 3 | 2024-12-09 | 2026-04-17 |
| Serotonin Control of Impulsivity in Tourette Disorder Administration of a PET radiotracer - Tourette Disorder | Phase 2 | Recruiting | Hospices Civils de Lyon | 25 | 2024-09-24 | 2024-12-04 |
| Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy Aurora 1:1 Drops (Indica), Placebo - Opioid Use Disorder, Methadone | Phase 2 | Recruiting | BC Centre on Substance Use | 24 | 2024-05-23 | 2025-02-17 |
| MDMA for Co-occurring PTSD and OUD After Childbirth MDMA Assisted Therapy - Stress Disorders, Post-Traumatic, Opioid Use Disorder | Phase 2 | Recruiting | University of New Mexico | 15 | 2024-04-16 | 2026-03-16 |
| Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users Treatment as Usual plus Placebo, Treatment as Usual plus Placebo plus Contingency Management, Treatment as Usual plus lisdexamfetamine (LDX-01) - Methamphetamine Abuse, Methamphetamine-dependence | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 440 | 2023-12-05 | 2026-02-05 |
| Semaglutide Therapy for Alcohol Reduction (STAR) Take Control, Semaglutide - Addiction, Alcohol Use Disorder | Phase 2 | Active not recruiting | National Institute on Drug Abuse (NIDA) | 63 | 2023-10-17 | 2026-09-02 |
| Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction APH-1501, Placebo - Addiction, Opioid Dependence | Phase 2 | Unknown | Aphios | 32 | 2023-10-01 | 2021-07-27 |
| Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Placebo, Auvelity - Addiction, Opioid Use | Phase 1 / Phase 2 | Completed | Virginia Commonwealth University | 18 | 2023-09-18 | 2026-08-19 |
| Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder Psilocybin, Maltodextrin - Alcohol Use Disorder | Phase 2 | Completed | Anders Fink-Jensen, MD, DMSci | 60 | 2023-09-01 | 2026-03-24 |
Showing 20 of 120. Sign in to see all of them.
Behavior, Addictive (92) · Substance-Related Disorders (35) · Alcoholism (27) · Cocaine-Related Disorders (20) · Opioid-Related Disorders (13) · Smoking Cessation (9) · Anxiety Disorders (8) · Marijuana Abuse (7) · Stress Disorders, Post-Traumatic (7) · Compulsive Behavior (6) · Smoking (6) · Alcohol Drinking (5) · Attention Deficit Disorder with Hyperactivity (5) · Depression (5)
Behavior (120) · Mental Disorders (97) · Compulsive Behavior (93) · Chemically-Induced Disorders (80) · Substance-Related Disorders (46) · Alcohol-Related Disorders (25) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (14) · Narcotic-Related Disorders (12) · Neurologic Manifestations (11) · Health Behavior (9) · Nervous System Diseases (9) · Neurodevelopmental Disorders (9) · Behavioral Symptoms (7)
Naltrexone (8) · Sugars (6) · Bupropion (5) · Cognitive Behavioral Therapy (4) · Tobacco Use Cessation Devices (4) · Varenicline (4) · Baclofen (3) · Buprenorphine (3) · Buprenorphine, Naloxone Drug Combination (3) · Citalopram (3) · Propranolol (3) · Therapeutics (3) · Vigabatrin (3) · semaglutide (3) · vivitrol (3)
Medical University of South Carolina (7) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (5) · University of California, Los Angeles (5) · Virginia Commonwealth University (5) · National Institute on Drug Abuse (NIDA) (4) · University of Minnesota (4) · Anders Fink-Jensen, MD, DMSci (3) · Johns Hopkins University (3) · University of Pennsylvania (3) · University of Southern California (3) · Catalyst Pharmaceuticals, Inc. (2) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · Dartmouth-Hitchcock Medical Center (2) · Milton S. Hershey Medical Center (2) · NYU Langone Health (2)
United States (80) · Canada (9) · Denmark (5) · Brazil (4) · France (3) · Israel (3) · Australia (2) · Germany (2) · Mexico (2) · Switzerland (2) · Bulgaria (1) · Czechia (1) · Netherlands (1) · Norway (1) · South Korea (1)
Lorenzo Leggio, M.D. (4) · Anders Fink-Jensen, Professor (2) · Annie Umbricht, M.D. (2) · Frederick G Moeller, M.D. (2) · Frederick G Moeller, MD (2) · Mark P. McGovern, Ph.D. (2) · Michael E Saladin, PhD (2) · Abraham Weizman, MD (1) · Abraham Zangen, Ph.D. (1) · Adam M Leventhal, PhD (1) · Adan Jardim (1) · Alison Oliveto, PhD (1) · Amanda Baker, Assoc Prof (1) · Andreas W Blomkvist, M.D. (1) · Andrew J. Saxon, M.D. (1)
PMID 38419905, PMID 41329966, PMID 15734224, PMID 17015817, PMID 17613964, PMID 18469236, PMID 19487623, PMID 19651710, PMID 19846066, PMID 20048226, PMID 20092966, PMID 20732631, PMID 20869813, PMID 21204739, PMID 21807480, PMID 22217949, PMID 22445683, PMID 22704138, PMID 23144826, PMID 23159524, PMID 23188041, PMID 23575810, PMID 23761390, PMID 23953269, PMID 24061784, PMID 24139147, PMID 24618688, PMID 24647726, PMID 24814607, PMID 24894963, PMID 25414797, PMID 25563446, PMID 25727442, PMID 25762749, PMID 25784600, PMID 25823919, PMID 26918564, PMID 26948856, PMID 27010975, PMID 27213949, PMID 27736051, PMID 28044255, PMID 28440812, PMID 29133954, PMID 30091969, PMID 30865304, PMID 30944474, PMID 31065731, PMID 31097294, PMID 31304887
P50DA018185 (3), 2019 (2), K23DA016574 (2), P50DA009262 (2), 1RC1AA019019-01 (1), 2009 (1), 2015 (1), 2023 (1), 2025 (1), 5UG1DA050207 (1), K01DA019446 (1), K23DA023558 (1), K24DA000435 (1), P20DA024157 (1), P50DA012756 (1)